PDF(Pubmed)
Abstract：
Teriparatide, a recombinant human parathyroid hormone, is an anabolic treatment for osteoporosis with a high risk of fractures. Transient hypercalcemia is an adverse effect of teriparatide and usually resolves within 16h of teriparatide administration owing to its rapid absorption and elimination. Some cases of prolonged hypercalcemia have been reported, but these improved rapidly after teriparatide discontinuation. Here, we describe a rare case of teriparatide-induced hypercalcemia concomitant with acute kidney injury that persisted for four weeks. An 83-year-old woman began taking teriparatide for a vertebral fracture. The patient was immobilized by the fracture. Three weeks later, the patient developed hypercalcemia and acute kidney injury. However, hypercalcemia persisted for four weeks despite the discontinuation of teriparatide and fluid administration. Clinicians should be aware that teriparatide can induce severe hypercalcemia, especially in the setting of immobilization, and that hypercalcemia can persist for more than 3-4 weeks in patients with decreased kidney function.
摘要：
特立帕肽,重组人甲状旁腺激素,是一种合成代谢疗法，用于治疗骨折高风险的骨质疏松症。短暂性高钙血症是特立帕肽的不良反应，由于其快速吸收和消除，通常在特立帕肽给药16小时内消退。已经报道了一些长期高钙血症的病例，但特立帕肽停药后这些改善迅速.这里,我们描述了一例特立帕肽诱导的高钙血症合并急性肾损伤的罕见病例,持续4周.一名83岁的妇女开始服用特立帕肽治疗椎骨骨折。患者因骨折而无法动弹。三周后,患者出现高钙血症和急性肾损伤.然而,尽管停用了特立帕肽和补液,但高钙血症持续4周.临床医生应注意特立帕肽可引起严重的高钙血症，尤其是在固定的情况下，在肾功能下降的患者中，高钙血症可以持续超过3-4周。
